Wayne J Morgan, Cm

List of Publications by Citations

Source: https://exaly.com/author-pdf/5433133/wayne-j-morgan-cm-publications-by-citations.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93	6,790	35	82
papers	citations	h-index	g-index
97	7,772	4.9	5.19
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
93	Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *New England Journal of Medicine*, **1995**, 332, 133-8	59.2	2919
92	Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. *Journal of Pediatrics*, **2007**, 151, 134-9, 139.e1	3.6	328
91	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. *Journal of Pediatrics*, **2003**, 142, 624-30	3.6	292
90	Factors influencing outcomes in cystic fibrosis: a center-based analysis. *Chest*, **2003**, 123, 20-7	5.3	169
89	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. *Lancet Respiratory Medicine,the*, **2017**, 5, 107-118	35.1	158
88	Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. *Pediatric Pulmonology*, **1999**, 28, 231-41	3.5	147
87	Impact of pregnancy on women with cystic fibrosis. *Chest*, **2006**, 129, 706-11	5.3	134
86	Feasibility of using unattended polysomnography in children for research--report of the Tucson Children's Assessment of Sleep Apnea study (TuCASA). *Sleep*, **2001**, 24, 937-44	1.1	122
85	Seasonal risk factors for asthma exacerbations among inner-city children. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 1465-73.e5	11.5	111
84	Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. *Pediatric Pulmonology*, **2007**, 42, 513-8	3.5	111
83	A Distinct Low Lung Function Trajectory from Childhood to the Fourth Decade of Life. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 607-12	10.2	102
82	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 405-11	4.1	83
81	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. *Pediatric Pulmonology*, **2013**, 48, 666-73	3.5	82
80	Year-to-year changes in lung function in individuals with cystic fibrosis. *Journal of Cystic Fibrosis*, **2010**, 9, 250-6	4.1	81
79	Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 289-97	10.2	77
78	Lung function decline from adolescence to young adulthood in cystic fibrosis. *Pediatric Pulmonology*, **2012**, 47, 135-43	3.5	77
77	Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. *Pediatric Pulmonology*, **1999**, 28, 248-54	3.5	72

76	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. *Pediatric Pulmonology*, **2015**, 50, 763-70	3.5	71
75	Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. *Pediatric Pulmonology*, **2011**, 46, 545-53	3.5	66
74	Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. *Journal of Pediatrics*, **2008**, 153, 746-51	3.6	65
73	Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. *Journal of Cystic Fibrosis*, **2012**, 11, 446-53	4.1	61
72	Airway responsiveness to cold, dry air in normal infants. *Pediatric Pulmonology*, **1988**, 4, 90-7	3.5	59
71	Clinical Screening of School Children for Polysomnography to Detect Sleep-Disordered Breathing□The Tucson Children□s Assessment of Sleep Apnea Study (TuCASA). *Journal of Clinical Sleep Medicine*, **2005**, 01, 247-254	3.1	51
70	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. *Pediatric Pulmonology*, **2015**, 50, 42-8	3.5	49
69	Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 163-71	5.4	49
68	Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. *Pediatrics*, **2007**, 119, e531-7	7.4	48
67	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. *Pediatric Pulmonology*, **2010**, 45, 1167-72	3.5	47
66	Risk factors for mortality before age 18 years in cystic fibrosis. *Pediatric Pulmonology*, **2017**, 52, 909-915	3.5	44
65	Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. *Pediatric Pulmonology*, **2010**, 45, 934-44	3.5	43
64	Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 293-9	4.1	42
63	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. *Journal of Pediatrics*, **2015**, 167, 1081-8.e1	3.6	39
62	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2018**, 15, 485-493	4.7	38
61	Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. *Pediatrics*, **2017**, 139,	7.4	37
60	Patterns of medical practice in cystic fibrosis: part I. Evaluation and monitoring of health status of patients. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. *Pediatric Pulmonology*, **1999**, 28, 242-7	3.5	35
59	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. *Pediatric Pulmonology*, **2010**, 45, 1156-66	3.5	34

58	Longitudinal differences in sleep duration in Hispanic and Caucasian children. *Sleep Medicine*, **2016**, 18, 61-6	4.6	33
57	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. *Pediatric Pulmonology*, **2015**, 50, 431-40	3.5	33
56	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. *Journal of Pediatrics*, **2016**, 169, 116-21.e2	3.6	33
55	Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. *Pediatric Pulmonology*, **2013**, 48, 649-57	3.5	33
54	Insomnia, Health-Related Quality of Life and Health Outcomes in Children: A Seven Year Longitudinal Cohort. *Scientific Reports*, **2016**, 6, 27921	4.9	30
53	Modified STOP-Bang Tool for Stratifying Obstructive Sleep Apnea Risk in Adolescent Children. *PLoS ONE*, **2015**, 10, e0142242	3.7	27
52	Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. *Journal of Pediatrics*, **2011**, 159, 819-824.e1	3.6	27
51	Relationship of Antibiotic Treatment to Recovery after Acute FEV Decline in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2017**, 14, 937-942	4.7	25
50	Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. *Journal of Pediatrics*, **2013**, 163, 1152-7.e2	3.6	25
49	Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. *Pediatric Pulmonology*, **2013**, 48, 943-53	3.5	25
48	Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. *Journal of Pediatrics*, **1999**, 134, 734-9	3.6	24
47	Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and Utility in Prediction of Future Exacerbation. *Journal of Allergy and Clinical Immunology: in Practice*, **2019**, 7, 915-924.e7	5.4	24
46	Association of prenatal and early childhood stress with reduced lung function in 7-year-olds. *Annals of Allergy, Asthma and Immunology*, **2017**, 119, 153-159	3.2	22
45	Mother Knows Best? Comparing Child Report and Parent Report of Sleep Parameters With Polysomnography. *Journal of Clinical Sleep Medicine*, **2019**, 15, 111-117	3.1	22
44	Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2015**, 12, 1170-6	4.7	21
43	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. *Annals of the American Thoracic Society*, **2018**, 15, 225-233	4.7	21
42	Prenatal fine particulate exposure associated with reduced childhood lung function and nasal epithelia GSTP1 hypermethylation: Sex-specific effects. *Respiratory Research*, **2018**, 19, 76	7.3	20
41	Early childhood wheezing is associated with lower lung function in cystic fibrosis. *Pediatric Pulmonology*, **2014**, 49, 745-50	3.5	18

40	Infants with upper respiratory illnesses have significant reductions in maximal expiratory flow. *Pediatric Pulmonology*, **1990**, 9, 91-5	3.5	18
39	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. *Pediatric Pulmonology*, **2008**, 43, 739-44	3.5	17
38	Clinical use of tobramycin inhalation solution (TOBI) shows sustained improvement in FEV1 in cystic fibrosis. *Pediatric Pulmonology*, **2014**, 49, 529-36	3.5	16
37	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005. *Journal of Cystic Fibrosis*, **2013**, 12, 332-7	4.1	16
36	Data that empower: The success and promise of CF patient registries. *Pediatric Pulmonology*, **2017**, 52, S44-S51	3.5	15
35	Spirometry and Impulse Oscillometry in Preschool Children: Acceptability and Relationship to Maternal Smoking in Pregnancy. *Journal of Allergy and Clinical Immunology: in Practice*, **2018**, 6, 1596-1603.e6	5.4	14
34	Prenatal nitrate air pollution exposure and reduced child lung function: Timing and fetal sex effects. *Environmental Research*, **2018**, 167, 591-597	7.9	14
33	Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 783-790	4.1	13
32	The effect of the affordable care act dependent coverage provision on patients with cystic fibrosis. *Pediatric Pulmonology*, **2017**, 52, 458-466	3.5	13
31	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. *Pediatric Pulmonology*, **2015**, 50, 856-62	3.5	13
30	BMI fails to identify poor nutritional status in stunted children with CF. *Journal of Cystic Fibrosis*, **2017**, 16, 158-160	4.1	11
29	Pulmonary function outcomes for assessing cystic fibrosis care. *Journal of Cystic Fibrosis*, **2015**, 14, 376-82	4.1	11
28	Impaired cardiac and peripheral hemodynamic responses to inhaled agonist in cystic fibrosis. *Respiratory Research*, **2015**, 16, 103	7.3	11
27	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. *Journal of Cystic Fibrosis*, **2018**, 17, 503-510	4.1	10
26	Sleep-Disordered Breathing is Associated With Increased Mortality in Hospitalized Infants With Congenital Heart Disease. *Journal of Clinical Sleep Medicine*, **2018**, 14, 1551-1558	3.1	10
25	Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2617-2627.e4	5.4	9
24	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2018**, 17, 496-502	4.1	9
23	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. *Pediatric Pulmonology*, **2020**, 55, 828-834	3.5	8

22	Health insurance and use of recommended routine care in adults with cystic fibrosis. *Clinical Respiratory Journal*, **2018**, 12, 1981-1988	1.7	7
21	The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis. *Heart and Lung: Journal of Acute and Critical Care*, **2016**, 45, 283-90	2.6	7
20	Liver involvement in the Hispanic population of North America with cystic fibrosis. *Journal of Pediatric Gastroenterology and Nutrition*, **2014**, 59, 476-9	2.8	7
19	Predictors of pulmonary exacerbation treatment in cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 407-414	4.1	7
18	OSA and Neurocognitive Impairment in Children With Congenital Heart Disease. *Chest*, **2020**, 158, 1208-1217	5.3	6
17	Comparison of FEV reference equations for evaluating a cystic fibrosis therapeutic intervention. *Pediatric Pulmonology*, **2017**, 52, 1013-1019	3.5	6
16	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. *Pediatric Pulmonology*, **2018**, 53, 43-49	3.5	5
15	Location and duration of treatment of cystic fibrosis respiratory exacerbations. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 278; author reply 279	10.2	5
14	sensitisation at age 6 years is associated with subsequent airway hyper-responsiveness in non-asthmatics. *Thorax*, **2018**, 73, 1170-1173	7.3	4
13	The Coupling of Peripheral Blood Pressure and Ventilatory Responses during Exercise in Young Adults with Cystic Fibrosis. *PLoS ONE*, **2016**, 11, e0168490	3.7	4
12	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. *Pediatric Pulmonology*, **2021**, 56, 823-836	3.5	3
11	Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada **1999**, 28, 231		3
10	Factors predicting the persistence of asthma insights from the Tucson children respiratory study. *Revue Francaise Dallergologie Et Dimmunologie Clinique*, **2005**, 45, 542-546		2
9	Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. *Pediatric Pulmonology*, **2020**, 55, 3400-3406	3.5	2
8	Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. *Clinical Infectious Diseases*, **2021**, 73, 987-993	11.6	2
7	Exercise Stroke Volume in Adult Cystic Fibrosis: A Comparison of Acetylene Pulmonary Uptake and Oxygen Pulse. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*, **2018**, 12, 1179548418790564	3.4	2
6	Does COPD begin in childhood?. *Lancet Respiratory Medicine,the*, **2013**, 1, 282-4	35.1	1
5	Diagnostic Accuracy of Nasopharyngeal Swab Cultures in Children Less Than Five Years with Chronic Wet Cough.. *Children*, **2021**, 8,	2.8	1

4	Bronchoalveolar lavage profiles in uncontrolled wheezy children compared by asthma predictive index. *Pediatric Pulmonology*, **2022**, 57, 293-299	3.5	0
3	Dr Jeffrey S. Wagener: An impactful career and life. *Pediatric Pulmonology*, **2020**, 55, 826-827	3.5	
2	Further evidence that sex matters in lung development: maternal asthma and infant lung function. *Thorax*, **2021**, 76, 959-960	7.3	
1	Reply. *Journal of Pediatrics*, **2016**, 172, 228-9	3.6	